NEW HAVEN, Conn., May 6, 2021 /PRNewswire/ -- Trevi
Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of an investigational therapy Haduvio™
(nalbuphine ER) to treat serious neurologically mediated
conditions, today announced that management will host a conference
call and live audio webcast on Thursday, May
13 at 4:30 p.m. ET, to provide
a corporate update and review the Company's financial results for
the quarter ended March 31, 2021.
Trevi Therapeutics Hosting Conference Call on Q1 2021 Financial
Results
To participate in the live conference call by phone, please dial
(888) 317-6003 (domestic) or (412) 317-6061 (international) and
provide access code 6116464. A live audio webcast will be
accessible from the 'Investors & News' section on the Company's
website at www.trevitherapeutics.com. An archived replay of the
webcast will also be available for 30 days on the Company's website
following the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and commercialization of an
investigational therapy Haduvio to treat serious neurologically
mediated conditions. Trevi is conducting a Phase
2b/3 clinical trial of Haduvio for
the treatment of chronic pruritus associated with prurigo nodularis
and a Phase 2 trial for chronic cough in patients with idiopathic
pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the
treatment of levodopa-induced dyskinesia (LID) in patients with
Parkinson's disease and is in the planning stages of a Phase 2
study in this indication. These conditions share a common
pathophysiology that is mediated through opioid receptors in the
central and peripheral nervous systems.
Founded in 2011, Trevi Therapeutics is headquartered
in New Haven, CT.
About Haduvio
Haduvio, an investigational therapy, is an oral extended release
formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor
agonist and µ-opioid receptor antagonist that has been approved and
marketed as an injectable for pain indications for more than 20
years in the United States and Europe. The ĸ- and
µ-opioid receptors are known to be critical mediators of itch,
cough and certain movement disorders. Nalbuphine's mechanism of
action may also mitigate the risk of abuse associated with µ-opioid
agonists because it antagonizes, or blocks, µ-opioid receptors.
Nalbuphine is not currently classified as a controlled substance by
the DEA in the United States and by regulatory
authorities in most of Europe. Trevi intends to
propose Haduvio as the trade name for the nalbuphine ER
investigational therapy. Haduvio is an investigational therapy and
its safety and efficacy have not been evaluated by any regulatory
authority.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q1-2021-financial-results-on-may-13-301285710.html
SOURCE Trevi Therapeutics, Inc.